Drug intelligence / Profile preview

GO-2317

Development stage: Unknown
Lead developer: General Oncology
Modality: Small Molecules
Administration: Intravenous

Overview

GO-2317 is a first-in-class small molecule prodrug developed by General Oncology. It is a new chemical entity (NCE) designed to convert into hydroxocobalamin (Vitamin B12b) upon dilution. GO-2317 is primarily utilized as a key component of the GO-4 combination therapy, which also includes melphalan, BCNU (carmustine), and ascorbic acid (Vitamin C). This combination is intended to treat patients with inherited mutations in BRCA1, BRCA2, or PALB2 by inducing DNA damage, suppressing DNA repair pathways, inhibiting ATP/glycolysis, and activating PARP. It is currently being evaluated in Phase 1 clinical trials for metastatic pancreatic cancer, metastatic breast cancer, and other solid metastatic tumors.

Other names: hydroxocobalamin prodrug

Targets

PARP1 (Poly (adp-ribose) polymerase 1)DNA

Beyond the preview

Go deeper on GO-2317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-2317.

Explore the full profile